FENC PEER ANALYSIS

Fennec Pharmaceuticals Inc — metric-by-metric comparison with peers and the industry median

FENCFennec Pharmaceuticals Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial Health
FENCIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
FENC+25.3%MSB+27.6%TLX-29.5%RTALB+24.1%
Year-to-Date (YTD)
FENC+39.0%MSB-24.3%TLX+50.7%RTALB+5.0%

Key Metric Comparison

P/E

Lower is better
FENCMSBTLXRTALB4.89Median 17.91

ROE

Higher is better
FENC-52.7%MSB-11.3%TLX-1.8%RTALB15.1%Median -47.5%

Net Margin

Higher is better
FENC-16.4%MSB-115.3%TLX-0.9%RTALB136.3%Median -125.7%

Revenue Growth

Higher is better
FENC65.0%MSB410.4%TLX56.3%RTALB24.0%Median 5.1%

All Metrics

Valuation
MetricFENCMSBTLXRTALBInd. Median
P/E4.8917.91
P/B10.106.370.613.51
EV/EBITDA120.1474.6114.82
P/S7.4631.613.246.6710.89
Financial Health
MetricFENCMSBTLXRTALBInd. Median
Current Ratio6.981.431.215.90
Debt/Equity112.3%1.2%10.9%
NetDebt/EBITDA13.130.901.15
Profitability
MetricFENCMSBTLXRTALBInd. Median
Net Margin-16.4%-115.3%-0.9%136.3%-125.7%
ROE-52.7%-11.3%-1.8%15.1%-47.5%
ROA-14.2%-8.6%-0.7%13.1%-35.8%
EBITDA Margin-13.1%-76.6%3.0%9.0%-105.8%
Growth + Dividend
MetricFENCMSBTLXRTALBInd. Median
Rev. Growth65.0%410.4%56.3%24.0%5.1%
NI Growth134.0%12.1%
Div. Yield0.0%0.0%0.2%
Payout0.0%0.0%0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on FENC

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.